Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) [Phase 3]

View source ↗

Summary

Phase 3 MELODY trial evaluating MEDI8897 for prevention of medically attended lower respiratory tract infections due to RSV in healthy late preterm and term inf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• MEDI8897

Snippet

Sponsor: AstraZeneca | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2024-02-28